Previous 10 | Next 10 |
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System Regulatory News: Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focuse...
Cellectis Researchers Build CAR T-Cells Able to Sense and React to Their Environment by Secreting Therapeutic Proteins That Improve Their Ability to Fight Cancerous Cells Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmac...
First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with UCART22 in BALLI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ...
Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), announced that it will report third quarter 2019 financial...
Cellectis S.A. (NASDAQ: CLLS ) resumed with Buy rating and $28 (151% upside) price target at Guggenheim. Shares up 3% premarket. More news on: Cellectis S.A., Gossamer Bio, Inc., Health Catalyst, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Cellectis’ UCARTCS1 MELANI-01 Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited off-the-shelf ...
Company Overview Allogene Therapeutics ( ALLO ) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer. Allogene believes that the next revolution in cancer treatment is the development of AlloCAR T therapie...
CRISPR Therapeutics ( CRSP ) has been on my watchlist for a couple of years but the stars never aligned for me to pull the trigger on a buy. Due to some recent updates, I am moving CRSP up to the top of my year-end shopping list and will be stalking an entry point in the coming weeks or months...
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline Manufacturing to take place at Lonza’s GMP site in Geleen, Netherlands Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a cl...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...